inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged 18 years of age or older 4. previously diagnosed with mm/al amyloidosis (cohorts 1 or 3) or other hematologic malignancy (cohorts 2 or 3). 5. previously received any one of the available covid-19 vaccines (between 4 and 36 weeks prior to enrollment) 6. anti-sars-cov2 igg antibody titer of results less than 1.0 units (cohorts 1 and 2), or 1.0-1.99 units (cohort 3). antibody titers will be measured within 14 days of enrollment. 7. if currently receiving potentially immunosuppressive anti-neoplastic therapy for their underlying hematologic condition, a two-week interruption in therapy before and after the booster dose of vaccine is encouraged but not required (physician discretion).-

inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged 18 years of age or older 4. previously diagnosed with mm/al amyloidosis (cohorts 1 or 3) or other hematologic malignancy (cohorts 2 or 3). 5. previously received any one of the available covid-19 vaccines (between 4 and 36 weeks prior to enrollment) 6. anti-sars-cov2 igg antibody titer of results less than 1.0 units (cohorts 1 and 2), or 1.0-1.99 units (cohort 3). antibody titers will be measured within 14 days of enrollment. 7. if currently receiving potentially immunosuppressive anti-neoplastic therapy for their underlying hematologic condition, a two-week interruption in therapy before and after the booster dose of vaccine is encouraged but not required (physician discretion).-

inclusion criteria: provision of signed and dated informed consent form stated willingness to comply with all study procedures and availability for the duration of the study male or female, aged 18 years of age or older previously diagnosed with mm/al amyloidosis (cohorts 1 or 3) or other hematologic malignancy (cohorts 2 or 3). previously received any one of the available covid-19 vaccines (between 4 and 36 weeks prior to enrollment) anti-sars-cov2 igg antibody titer of results less than 1.0 units (cohorts 1 and 2), or 1.0-1.99 units (cohort 3). antibody titers will be measured within 14 days of enrollment. if currently receiving potentially immunosuppressive anti-neoplastic therapy for their underlying hematologic condition, a two-week interruption in therapy before and after the booster dose of vaccine is encouraged but not required (physician discretion).-

inclusion criteria: provision of signed and dated informed consent form stated willingness to comply with all study procedures and availability for the duration of the study male or female, aged 18 years of age or older previously diagnosed with mm/al amyloidosis (cohorts 1 or 3) or other hematologic malignancy (cohorts 2 or 3). previously received any one of the available covid-19 vaccines (between 4 and 36 weeks prior to enrollment) anti-sars-cov2 igg antibody titer of results less than 1.0 units (cohorts 1 and 2), or 1.0-1.99 units (cohort 3). antibody titers will be measured within 14 days of enrollment. if currently receiving potentially immunosuppressive anti-neoplastic therapy for their underlying hematologic condition, a two-week interruption in therapy before and after the booster dose of vaccine is encouraged but not required (physician discretion).-

inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged 18 years of age or older 4. previously diagnosed with mm/al amyloidosis (cohorts 1 or 3) or other hematologic malignancy (cohorts 2 or 3). 5. previously received any one of the available covid-19 vaccines (between 4 and 36 weeks prior to enrollment) 6. anti-sars-cov2 igg antibody titer of results less than 1.0 units (cohorts 1 and 2), or 1.0-1.99 units (cohort 3). antibody titers will be measured within 14 days of enrollment. 7. if currently receiving potentially immunosuppressive anti-neoplastic therapy for their underlying hematologic condition, a two-week interruption in therapy before and after the booster dose of vaccine is encouraged but not required (physician discretion).-

inclusion criteria: 1. provision of signed and dated informed consent form 2. stated willingness to comply with all study procedures and availability for the duration of the study 3. male or female, aged 18 years of age or older 4. previously diagnosed with mm/al amyloidosis (cohorts 1 or 3) or other hematologic malignancy (cohorts 2 or 3). 5. previously received any one of the available covid-19 vaccines (between 4 and 36 weeks prior to enrollment) 6. anti-sars-cov2 igg antibody titer of results less than 1.0 units (cohorts 1 and 2), or 1.0-1.99 units (cohort 3). antibody titers will be measured within 14 days of enrollment. 7. if currently receiving potentially immunosuppressive anti-neoplastic therapy for their underlying hematologic condition, a two-week interruption in therapy before and after the booster dose of vaccine is encouraged but not required (physician discretion).-